The company itself is the constraint: demand outrunning its own ability to take it on, and management is spending to rai
The model's full reasoning — Q3 2023 call → NOWe need to determine if management conveys that the company's own capability is the ceiling and that they are actively spending to raise it now. From the transcript: Masoud says "we're pleased to announce the six-quarter transformation plan we laid out last year is expected to be substantially complete by year end, with assays rolling off our new scalable production platform in January." This suggests they are building production capacity. They talk about "improving operating scale and margins" and "increasing innovation rate." They mention "we will continue to improve gross margins and take our research business from one that's burning cash to one that's generating it." They talk about deploying capital to expand access and enable patient testing. But is there a sense that demand is pressing against their capability? They mention "consumables revenue increased to $16.2 million or 63% compared to third quarter of last year. This speaks to the strength of our installed base as well as the improvements in our manufacturing processes as we were able to catch up with demand." That phrase "catch up with demand" suggests they had demand exceeding supply, and they are now catching up. Also, they mention "we were able to catch up with demand" - that implies they were behind. And they talk about "the number of new biomarker discoveries happening on our platform" and "we're in a great position to maintain a long-term leadership role." They also mention "we signed a new agreement with Johnson & Johnson Innovative Medicines" and "launched the Lucent AD P-tau217 blood based biomarker test" - that's a new product. But is management actively spending to raise the ceiling? They talk about "upgrades and readiness of our production lines as we introduce new assays in 2024" and "executing on the final steps of our transformation." They mention "we will be focused on upgrades and readiness of our production lines" in Q4. They also mention "we expect non-GAAP gross margins to be in the mid-40s for the fourth quarter, slightly lower than past quarters to account for potential higher costs from these transitional changes." That suggests they are incurring costs for the transition.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| TSSI | TSS, Inc. | Q4 2022 | 2023-04-03 | D |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| FORM | FormFactor, Inc. | Q4 2021 | 2022-02-02 | B |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| ZBH | Zimmer Biomet Holdings, Inc. | Q2 2017 | 2017-07-30 | F |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
ZBH · Q2 2017 → YESThe question is whether management conveys that the company's own ability to serve, supply, or take on business is the binding limit, and they're actively spending/building/hiring now to raise that li...YES The transcript shows management framing the Warsaw North Campus production delays and resulting back orders as the direct constraint on meeting existing customer demand and recapturing lost business, with steady market demand present but supply gating growth. They describe actively investing now in manufacturing remediation, quality enhancements, safety stock building, and sales force incentives and hires to restore full supply and return to offense, treating these as the central priority to expand capability and capture opportunities. This matches the criteria of internal capability as the binding limit and immediate action to raise it. The remediation is presented as urgent and ongoing rather than routine catch-up. The answer is YES.
FORM · Q4 2021 → YESThe question is whether management conveys that their own ability to serve/supply is the binding limit, and they're actively expanding now. YES The transcript shows management explicitly framing the company's internal limits—labor shortages in U.S. factories and extended lead times from sub-component delays—as the immediate ceiling on revenue growth, while simultaneously describing active, ongoing capital investments, facility expansions (Livermore), tool and labor additions, and supplier qualification efforts as the central priority to raise that ceiling and meet surging customer demand. This dual situation is presented as a present-tense reality driving the $850 million target path. The supply-chain component is acknowledged but subordinated to the claim that demand is outrunning current capability, and the build-out is treated as the key task ahead rather than routine maintenance.
FLUX · Q2 2022 → YESThe question is: Does management convey that the company's own ability to serve, supply, or take on business has become the binding limit on how big it can be right now — that real demand is pressing ...YES The transcript shows management explicitly framing the company's production capacity as the current binding limit: "We can’t build packs fast enough to keep up with the demand" and noting that supply-chain constraints (especially electronic components) are preventing them from serving the robust order flow and record backlog.